Skip to main content
Premium Trial:

Request an Annual Quote

GenomeDx, Janssen Partner to Test Tumor Genome Profile Database

NEW YORK (GenomeWeb) – GenomeDx said today that it has signed an agreement to test its Decipher GRID database of cancer genomic profiles with samples from prostate cancer clinical trials run by Janssen Pharmaceuticals.

Under the terms of the deal, GenomeDx will test the samples in order to evaluate the association of prognostic and predictive genomic signatures from the Decipher GRID platform — which includes more than 40,000 RNA expression profiles of urologic cancers — with clinical outcomes.

Additional terms were not disclosed.

"We are excited to work together with Janssen on this important research collaboration, which we believe will accelerate the discovery and development of genomic solutions for the treatment and management of high-risk prostate cancer," GenomeDx President and CSO Elai Davicioni said in a statement. "Using Decipher and GRID to leverage the knowledge derived from thousands of tumor genomic profiles to uncover novel predictors of treatment response with machine learning approaches will help realize our mutual goal of personalizing therapy for men suffering from this disease."

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.